Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Nascent Biotech (OTC: NBIO): Pritumumab's Status as a Clinical-Stage Antibody

Nascent Biotech is a clinical-stage biopharmaceutical company developing Pritumumab, a natural human monoclonal antibody. The company has positioned Pritumumab as a treatment candidate for brain cancers such as glioblastoma, as well as epithelial cancers including lung, breast, colon and pancreatic tumors. Its most recent …

Nitish Kishor | 10 September 2026

Acura Pharmaceuticals (OTC: ACUR): The State of the Abuse-Deterrent Drug Developer

Acura is a drug-delivery company built around abuse-deterrent pharmaceutical technologies, including its Aversion and LIMITx platforms designed to reduce the potential for misuse of oral medications. Its portfolio has included Oxaydo, an immediate-release oxycodone product, and the Nexafed line of pseudoephedrine-based cold and allergy …

Nitish Kishor | 10 September 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX): Positive Phase 3 Data in Psoriatic Arthritis

MoonLake is a clinical-stage biopharmaceutical company developing sonelokimab, a Nanobody designed to inhibit IL-17A and IL-17F, cytokines central to inflammatory disease. On August 10, 2026, the company announced positive topline results from its Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA), reporting …

Nitish Kishor | 10 September 2026

iTonic Holdings (NASDAQ: ITOC): Listing Compliance and Legal Overhang Explained

iTonic Holdings Ltd (NASDAQ: ITOC) is a healthcare technology company focused on brachytherapy, a form of cancer treatment that places radioactive sources inside or next to a tumor. The company develops treatment-planning systems and related software used in radiotherapy, and it is headquartered in …

Nitish Kishor | 10 September 2026

Pulmatrix (NASDAQ: PULM): The Pending Reverse Merger With Eos SENOLYTIX

Pulmatrix, Inc (NASDAQ: PULM) is a clinical-stage biotechnology company historically known for its iSPERSE inhaled dry-powder platform. In recent quarters it has functioned largely as a small, cash-conserving Nasdaq-listed shell seeking a strategic combination.

Nitish Kishor | 10 September 2026

CalciMedica (NASDAQ: CALC): FDA Alignment on Acute Pancreatitis Endpoints

CalciMedica, Inc (NASDAQ: CALC) is a clinical-stage biopharmaceutical company developing Auxora, an intravenous inhibitor of calcium release-activated calcium (CRAC) channels. Its primary focus is acute pancreatitis (AP), a serious inflammatory condition with no approved targeted therapy.

Nitish Kishor | 10 September 2026

Bio Green Med Solution (NASDAQ: BGMS): Understanding the Fire-Safety Company's Pending Merger

Bio Green Med Solution, Inc (NASDAQ: BGMS) is headquartered in Kuala Lumpur, Malaysia, and operates in the industrials sector. Its business centers on distributing, trading and installing protective and fire-safety materials and equipment, along with fire protection and prevention systems. Despite the "Med" in …

Nitish Kishor | 10 September 2026

Rafarma Pharmaceuticals (OTC: RAFA): A Sub-Penny Generic Drugmaker's Limited Disclosure

Rafarma Pharmaceuticals describes itself as a multi-product pharmaceutical company focused onManufacturingand selling generic antibiotics, specialty medicines and anti-cancer drugs, with operations oriented toward Russian and international markets. The company is incorporated in Wyoming and its shares trade on the OTC Markets rather than a …

Nitish Kishor | 10 September 2026

Change Agents Corporation (NASDAQ: CHGA): Inside the Company's Reverse Stock Split

Change Agents Corporation is a developer of agentic artificial-intelligence software aimed at small businesses and content creators. Its products include Beacon, described as an AI search-optimization platform, and Catch-Up, an autonomous content-creation tool, both offered through a software-as-a-service model. The company also distributes KetoAir, …

Nitish Kishor | 10 September 2026

Niagen Bioscience (NASDAQ: NAGE): From Consumer Supplements to Rare-Disease Development

Niagen Bioscience develops and markets nicotinamide riboside chloride, branded Niagen, in both food-grade and pharmaceutical-grade formulations, with Tru Niagen as its best-known consumer product. The company trades on theNasdaqunder the ticker NAGE following its rebranding from ChromaDex, a change investors should keep in mind …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…